A gene-based recessive diplotype exome scan discovers \u3cem\u3eFGF6\u3c/em\u3e, a novel hepcidin-regulating iron-metabolism gene by Guo, Shicheng et al.
Marquette University 
e-Publications@Marquette 
Mathematical and Statistical Science Faculty 
Research and Publications 
Mathematical and Statistical Science, 
Department of 
4-25-2019 
A gene-based recessive diplotype exome scan discovers FGF6, a 
novel hepcidin-regulating iron-metabolism gene 
Shicheng Guo 
Shuai Jiang 
Narendranath Epperla 
Yanyun Ma 
Mehdi Maadooliat 
See next page for additional authors 
Follow this and additional works at: https://epublications.marquette.edu/math_fac 
Authors 
Shicheng Guo, Shuai Jiang, Narendranath Epperla, Yanyun Ma, Mehdi Maadooliat, Zhan Ye, Brent Olson, 
Minghua Wang, Terrie Kitchner, Jeffrey Joyce, Peng An, Fudi Wang, Robert Strenn, Joseph J. Mazza, 
Jennifer K. Meece, Wenyu Wu, Li Jin, Judith A. Smith, Jiucan Wang, and Steven J. Schrodi 
 Marquette University 
e-Publications@Marquette 
 
Mathematics and Statistical Sciences Faculty Research and 
Publications/College of Arts and Science 
 
This paper is NOT THE PUBLISHED VERSION; but the author’s final, peer-reviewed manuscript. The 
published version may be accessed by following the link in the citation below. 
 
Blood, Vol. 133, No. 17 (April 25 2019) : 1888-1898. DOI. This article is © American Society of 
Hematology and permission has been granted for this version to appear in e-Publications@Marquette. 
American Society of Hematology does not grant permission for this article to be further 
copied/distributed or hosted elsewhere without the express permission from American Society of 
Hematology. 
A gene-based recessive diplotype exome scan 
discovers FGF6, a novel hepcidin-regulating 
iron-metabolism gene 
 
Shicheng Guo 
Center for Human Genetics, Marshfield Clinic Research Institute, Marshfield, WI 
Shuai Jiang 
State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, 
School of Life Science and Human Phenome Institute, Fudan University, Shanghai, China 
Narendranath Epperla 
Division of Hematology, The Ohio State University, Columbus, OH 
Yanyun Ma 
State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, 
School of Life Sciences and Human Phenome Institute, Fudan University, Shanghai, China 
Mehdi Maadooliat 
Center for Human Genetics, Marshfield Clinic Research Institute, Marshfield, WI 
Department of Mathematics, Statistics and Computer Science, Marquette University, Milwaukee, WI 
Zhan Ye 
Biomedical Informatics Research Center, Marshfield Clinic Research Institute, Marshfield, WI 
Brent Olson 
Biomedical Informatics Research Center, Marshfield Clinic Research Institute, Marshfield, WI 
Minghua Wang 
Department of Biochemistry and Molecular Biology, Medical College, Soochow University, Suzhou, China 
Terrie Kitchner 
Center for Human Genetics, Marshfield Clinic Research Institute, Marshfield, WI 
Jeffrey Joyce 
Center for Human Genetics, Marshfield Clinic Research Institute, Marshfield, WI 
Peng An 
Beijing Advanced Innovation Center for Food Nutrition and Human Health, China Agricultural University, Beijing, 
China 
Fudi Wang 
Nutrition Discovery Innovation Center, School of Public Health, Zhejiang University School of Medicine, 
Hangzhou, China 
Robert Strenn 
Biomedical Informatics Research Center, Marshfield Clinic Research Institute, Marshfield, WI 
Joseph J. Mazza 
Clinical Research Center, Marshfield Clinic Research Foundation, Marshfield, WI 
Jennifer K. Meece 
Integrated Research and Development Laboratory, Marshfield Clinic Research Institute, Marshfield, WI 
Wenyu Wu 
Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China 
Li Jin 
State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, 
School of Life Sciences and Human Phenome Institute, Fudan University, Shanghai, China 
Judith A. Smith 
Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 
Jiucun Wang 
State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, 
School of Life Sciences and Human Phenome Institute, Fudan University, Shanghai, China; Institute of 
Rheumatology, Immunology and Allergy, Fudan University, Shanghai, China 
Steven J. Schrodi 
Center for Human Genetics, Marshfield Clinic Research Institute, Marshfield, WI 
Computation and Informatics in Biology and Medicine, University of Wisconsin-Madison, Madison, WI 
 
Abstract 
Standard analyses applied to genome-wide association data are well designed to detect additive effects of 
moderate strength. However, the power for standard genome-wide association study (GWAS) analyses to 
identify effects from recessive diplotypes is not typically high. We proposed and conducted a gene-based 
compound heterozygosity test to reveal additional genes underlying complex diseases. With this approach 
applied to iron overload, a strong association signal was identified between the fibroblast growth factor–
encoding gene, FGF6, and hemochromatosis in the central Wisconsin population. Functional validation showed 
that fibroblast growth factor 6 protein (FGF-6) regulates iron homeostasis and induces transcriptional regulation 
of hepcidin. Moreover, specific identified FGF6variants differentially impact iron metabolism. In addition, FGF6 
downregulation correlated with iron-metabolism dysfunction in systemic sclerosis and cancer cells. Using the 
recessive diplotype approach revealed a novel susceptibility hemochromatosis gene and has extended our 
understanding of the mechanisms involved in iron metabolism. 
Introduction 
Genome-wide association studies (GWASs) are well designed to detect additive effects of modest effect sizes. 
We hypothesized that gene-based tests sensitive to recessive diplotypes, including recessive single-site effects 
and compound heterozygosity, may reveal additional genes underlying complex diseases. Carrying variants 
conferring a compromised function on both homologous chromosomes is likely to impact molecular 
physiological states. Deep-sequencing studies have conclusively shown a vast reservoir of rare variants 
segregating in human populations.1 Rare variants in functional categories (eg, missense, regulatory motifs) may 
generate pathogenic effects through recessively acting diplotypes, and such effects are apt to remain concealed 
from standard GWAS analyses. Simple power calculations show that recessive diplotype inheritance produces 
signals that are difficult for standard GWAS methods to discover (supplemental Figure 1, available on 
the Blood Web site). Compound heterozygosity disease models also enjoy a high degree of biological plausibility, 
particularly if the alleles confer compromised protein function.2-5 Recessive diplotype modes of inheritance are 
well established in Mendelian diseases, such as cystic fibrosis,6 mevalonic aciduria,7 β-thalassemia,8and 
Niemann-Pick disease.9 Although not systematically examined in population-based studies, there is a sizable 
repository of genes underlying complex diseases with recessive, loss-of-function effects.10-14 Hence, we posited 
that an exome-wide, gene-based screen of recessive diplotypes using putative functional variants in both 
oligogenic and complex diseases may expand our knowledge of disease genes. 
Iron-metabolism disorders, including adult hereditary hemochromatosis, collectively are common conditions 
with considerable public health implications.15,16Importantly, the hepatic hormone hepcidin is a key regulator 
of iron homeostasis by controlling iron flux from enterocytes and macrophages to plasma through degradation 
of the cellular iron exporter ferroportin (SLC40A1). Within cells, ferritin is the iron-storage protein that can be 
used for indirect iron quantification. To investigate the inheritance of hemochromatosis, several segregation 
analyses were initially conducted, concluding that a recessive mode of inheritance is highly 
plausible.17,18 Several human studies have investigated the genetics of iron overload, revealing several critically 
important genes. Notably, HFE, encoding the membrane-bound hereditary hemochromatosis protein, was 
mapped 2 decades ago through family-based linkage19-22 and association approaches.23,24 Additional studies 
have definitively placed the missense polymorphism C282Y (rs1800562) in HFE as the major susceptibility factor 
in adult-onset, type 1 hereditary hemochromatosis.25,26 Additional genes have been identified through 
pathway-based genetic association studies and GWASs, including BMP2, BMP4, HJV, TF, TMPRSS6, NAT2, FADS2, 
and TFR2.27-29 
Methods 
Central Wisconsin hemochromatosis sample set 
The homogenous population in rural central Wisconsin is the source population for the Personalized Medicine 
Research Project (PMRP), a biobank linked to electronic health records (EHRs) housed by the Marshfield Clinic 
Research Institute.30 Samples from over 20 000 individuals comprise the PMRP. The study was conducted in 
accordance with the Declaration of Helsinki. All samples were collected following written informed consent. All 
investigators using the PMRP samples had obtained Research Ethics and Compliance Training certification 
through the Collaborative Institutional Training Initiative (CITI) program. The study protocol was reviewed and 
approved by the Marshfield Clinic Institutional Review Board (details in “Acknowledgments”). The Central 
Wisconsin population is largely stationary and primarily derived from Bavarian migrants in the late 1800s. The 
population carries high utility for disease gene mapping through reduction in confounding by population 
stratification and lower expected levels of allelic and locus heterogeneity. Additionally, environmental exposures 
are thought to be relatively uniform across this population. For these reasons, the PMRP has been effectively 
used in numerous human genetics studies.31-34 PMRP DNA samples were collected and stored ∼14 years ago 
and all individuals have longitudinal EHR information housed at the Marshfield Clinic, averaging >30 years. The 
EHR is composed of International Classification of Diseases, Ninth Revision (ICD-9) diagnostic codes, laboratory 
test results, clinical procedure data, prescription information, and physician notes. Hemochromatosis cases and 
controls were selected from the PMRP population. Hemochromatosis cases were selected on the basis of the 
percent transferrin saturation laboratory values (the ratio of serum iron to transferrin iron-binding capacity) 
exceeding 48% and having 2 or more instances of ICD-9 codes indicating the diagnosis of hemochromatosis: 
275.0 (iron metabolism disorder, excluding anemia), 275.01 (hereditary hemochromatosis), 275.03 (unspecified 
hemochromatosis), and/or 275.09 (other iron-metabolism disorders). To reduce confounding by population 
stratification, a principal components analysis on the exome-genotyping data was implemented using all 
samples, blinded to disease status. Individuals considered genetic background outliers (>3 standard deviations 
from the centroid of the first 2 principal components) were excluded from the study. Following the removal of 
outliers, the resulting set of individuals was highly homogeneous based on the first 3 principal components. 
Exhaustive pairwise kinship coefficients were calculated and 1 individual from pairs of individuals exhibiting 
third-degree or closer relatedness were removed. Of the ∼10 000 individuals previously subjected to the exome-
genotyping array and quality control procedures, the phenotype algorithm identified 18 individuals who were 
selected as hemochromatosis cases. Controls (n = 6896) were individuals without abnormal saturation values 
and without any instances of hemochromatosis ICD-9 codes. 
Genotyping 
Of the full PMRP cohort, ∼10 000 DNAs were interrogated by high-density genotyping on the Illumina 
HumanCoreExome beadchip. This exome array of >500 000 markers has ancestry informative markers, a panel 
of identity-by-descent single nucleotide polymorphisms (SNPs), coverage of markers found to be genome-wide 
significant in GWASs, and excellent coverage of exonic variants. The version of the beadchip was designed and 
used in the AMD Consortium.34 Rare variants (<1% frequency) represented 47.8% of the markers, moderately 
common variants (1% to 10% frequency) were 8.1% of the variants, and 44.1% of the variants interrogated were 
common alleles (>10% frequency). The genotyping quality control measures were previously described (call 
rates for each variant or individual >0.985).34 Variants exhibiting departure from Hardy-Weinberg equilibrium 
(P < 1 × 10−6) were excluded from subsequent analyses. Additional recent studies have used data generated 
from this genotyping to discover susceptibility genes for common diseases.35 Following quality control 
procedures, 413 701 variants remained for analysis. The site frequency spectrum of the resulting variants is 
displayed in supplemental Figure 2 and supplemental Table 1. 
Haplotype phasing 
In general, gametic phasing is necessary to directly determine compound heterozygous individuals at a 
particular gene. Using all 10 000 exome-genotyped samples from the PMRP, the software package Beagle was 
applied to infer phased haplotypes from unphased genotype data using a localized haplotype-cluster model 
algorithm.36 The calculations were performed on a high-performance computing cluster housed at the 
Marshfield Clinic. As the subsequent analyses were gene-based and the genotyping data were concentrated on 
exonic variants, each gene in the exome was phased separately using this approach. Although rare variants can 
present difficulties in phasing, the use of a large sample size from a highly homogeneous population aids in 
mitigating the error rate. Notably, Beagle has been shown to have error rates in phasing between 0.77% to 
0.94% for medium (n = 1000) to large (n = 5000) sample sizes using a 500K GWAS array.36 Recently, the switch 
error rate was calculated for the Beagle applied to 2 sequencing data sets. Beagle attained a switch error rate of 
1.525% and 0.488% for the 1000 Genomes Project and Haplotype Reference Consortium, respectively.37 
Determination of putative functional variants 
Following the phasing of the genotype data, putative functional variants were identified. The putative functional 
variants included in the analyses satisfied the quality control criteria as described previously.34 Markers used in 
the analyses were either GWAS-significant as of June 2015 and/or annotated as missense, nonsense, 3′ 
untranslated region, 5′ untranslated region, or occurring within a splice site region. Additionally, on the resulting 
set of variants, annotation was performed using the ANNOVAR software.38 Only variants that were also 
annotated as pathogenic by at least 2 ANNOVAR predictions were included in the scan. Following filtering for 
putative functional variants, 129 556 SNPs remained for use in our gene-based recessive diplotypes scan. The 
putative functional variants of FGF6 are shown in supplemental Table 2. 
Statistical tests of recessive diplotypes 
At each gene, individuals were classified as having a recessive diplotype configuration if they carried at least 1 
putative functional allele on each homolog (PF). Individuals carrying at least 1 homolog free from putative 
functional alleles were deemed as having a wild type (WT) diplotype (W). The total number of case/control 
individuals carrying a recessive diplotype was denoted by PFcs and PFct, respectively. Similarly, the total number 
of case/control individuals carrying a WT diplotype was denoted by Wcs and Wct, respectively. Following the 
determination of these counts, a Fisher exact test was applied. As the hypergeometric null density holds for all 
sample sizes, the Fisher exact test is robust to imbalance between case and control sample sizes. Simulations 
have recapitulated this finding showing that the Fisher exact test does not inflate type I error rates under 
unbalanced designs.39Individuals carrying 1 or more homozygous genotype(s) at a single site for a putative 
functional allele were included in the PF category. Genes without any high-quality, putative functional alleles 
across all samples were removed from the analyses. Across all genes with analyzable data, a conservative 
experiment-wise multiplicity correction was calculated using 15 900 gene-based tests. To compare the recessive 
diplotype analysis procedure to a standard rare variant gene-based test, the RVTESTS software,40 which 
implements the sequence kernel association test, was also applied to the genotype data.41 Additionally, to 
investigate the sex-specific effects, the Haldane odds ratio (OR) was calculated separately for female and male 
strata. Lastly, the Mantel-Haenszel test of homogeneity was calculated to determine the level of statistical 
evidence for sex-specific differences in effects.42 
Power calculations 
To explore the efficacy of the proposed approach, we performed analytic power calculations under the 
alternative model of compound heterozygosity/recessive inheritance of disease at 2 sites, each segregating 2 
alleles. By doing so, we sought to compare the power of a standard GWAS analysis (Armitage trend test) to a 
log-likelihood ratio G test.42 Supplemental Figure 1 shows the power of each of these tests across different sets 
of penetrances and haplotype frequencies. To consolidate the different sets of haplotype frequencies, the 
results are plotted as a function of linkage disequilibrium between the 2 sites. The power of the G test for 
recessive diplotypes exceeded the power for the Armitage trend test across virtually all of the parameter space. 
Additional work in this area was recently performed by Sanjak et al showing similar results.43 
Comparative genomic analysis and protein-protein interaction inference 
Amino acid sequencing of the core iron-metabolism genes were collected, including transferrin receptor 1 
(TFRC), FTH1, IREB1, SKP1, SKP1, ACO1, TFR2, TF, HMOX1, ACO2, HAMP, FGF6, and FGFR1. The alignments were 
derived from National Center for Biotechnology Information (NCBI) BLASTn database. Phylogeny for different 
genes were compared, showing the earliest evolutionary time point; then, occurrence for each gene was 
mapped to the phylogenetic tree.44 Protein-protein interaction network inference was conducted to fibroblast 
growth factor 6 protein (FGF-6) and main iron-metabolism proteins. The finial network was tuned after 
removing nonnecessary nodes between FGF-6 and key iron molecules including hereditary hemochromatosis 
protein (HFE) and SLC40A1. 
Cell culture, reagents, and protein treatment 
Colon cancer cell lines (HCT8 and HCT116), a kidney cancer cell line (786-O), a liver cancer cell line (HepG2), and 
a fibroblast cell line (HFF-1) were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 
10% fetal bovine serum (FBS) at 37°C in a 5% CO2 humidified incubator. To investigate the change in iron uptake 
under different protein treatments or plasmid transfection, the ferric ammonium citrate (FAC) cell culture 
method was used. Cells were cultured in normal DMEM and FBS medium with the presence of 10 μM FAC and 
500 μM ascorbate for 48 hours during detection of cellular iron concentration. Cells cultured in normal medium 
exhibited very low iron concentrations. Total intracellular iron concentration in cells cultured with FAC for 48 
hours was dramatically increased over cells cultured in normal medium. Recombinant human FGF-6 protein 
(active) and anti-ferritin were purchased from Abcam, Flag tag antibody was purchased from Proteintech Group, 
and anti–glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was purchased from Shanghai Yeasen 
Biotechnology. FAC (1 mM) and ascorbate (50 mM) were dissolved in distilled water. NaOH, HCl, KMnO4, 
ferrozine, neocuproine, ammonium acetate, ascorbic acid, and FeCl3 were purchased from Beijing Oka Biological 
Technology. Plasmid with raw FGF6 sequence was purchased from PPL-Shanghai Co, Ltd, which was constructed 
in an N-terminal p3XFLAG-CMV vector, whereas 3 different FGF6 mutations (E127X, D174V, R188Q) were 
synthesized with overlapping polymerase chain reaction (PCR). 
Quantification of iron content by ferrozine assay 
Total intracellular iron content was measured by the ferrozine assay.45 Cells were cultured in 12- or 24-well 
plate for 48 hours and washed 3 times with cold phosphate-buffered saline (PBS). After being lysed for 2 hours 
with 50 mM NaOH, 100 μL of cell lysates was mixed with 10 mM HCl, and 100 μL of the iron-releasing reagent (a 
freshly mixed solution of equal volumes of 1.4 M HCl and 4.5% [wt/vol] KMnO4 in H2O). The mixtures were 
incubated for 2 hours and 30 μL of iron-detection reagent (6.5 mM ferrozine, 6.5 mM neocuproine, 2.5 M 
ammonium acetate, and 1 M ascorbic acid) was added; after 30-minute incubation, 280 μL of solution was 
added to a 96-well plate and read 550 nm on a microplate reader. In addition, FeCl3 (0-100 μM) was used as iron 
standards and protein quantification was determined by a Lowry protein assay. 
Western blot 
Cell lysates were harvested when incubated with iron for 48 hours, then equal amounts of protein from every 
sample were subjected to 12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis and then transferred 
to polyvinylidene difluoride membranes. After blocking with 5% bovine serum albumin (BSA), the membranes 
were incubated with GAPDH (1:10000), ferritin (1:1000), and Flag (1:2000) at 4°C overnight. Then, membranes 
were washed 3 times with Tris-buffered saline plus polysorbate 20, incubated with anti-rabbit or anti-mouse 
secondary antibody. The bands were visualized using Image QuantTL software. 
Perls staining 
Cells were washed with PBS 3 times, fixed with 4% glutaraldehyde for 10 minutes, and incubated at 37°C for 60 
minutes with 2 mL of Prussian blue solution comprising equal volumes of 2% hydrochloric acid aqueous solution 
and 2% potassium ferrocyanide (II) trihydrate. After the cells were stained with 0.5% neutral red for 3 minutes, 
iron staining was visualized by Nikon microscope. Iron-positive high positive staining cells divided by total cell 
number was used to evaluate the iron-deposition levels. 
RT-PCR and quantitative RT-PCR analysis 
Total RNA was extracted from the cells using TRIzol (Invitrogen). One microgram of total RNA was subjected to 
complementary DNA synthesis using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems) 
according to the manufacturer’s instructions. The specific primers for each gene were designed using Primer 5 
and synthesized by Generay Biotech Co, Ltd. The reverse transcription polymerase chain reaction (RT-PCR) 
amplification was conducted using a SYBR Green I PCR kit (TaKaRa) according to the manufacturer’s instructions. 
The reaction was carried out on an ABI Prism 7900 Detector System (Applied Biosystems). RT-PCR conditions 
were 95°C for 3 minutes, followed by 40 cycles of 95°C for 15 seconds, 60°C for 40 seconds; the conditions for 
obtaining the dissociation curve were 95°C for 15 seconds, 60°C for 15 seconds, 95°C for 15 seconds. The data 
obtained from the assays were analyzed with SDS 2.3 software (Applied Biosystems). For each sample, the 
relative gene expression was calculated using a relative ratio to GAPDH. RT-PCR primers can be found in the 
supplemental Table 3. 
Immunohistochemical staining of FGF-6 
The primary antibody used was anti-FGF-6 (1:200; BBI) and anti-ferritin (1:100; abcam). Liver and skin tissues 
from 4 liver cancer patients and 6 systemic sclerosis (SSc) patients, respectively, and normal controls were 
formalin-fixed and paraffin-embedded. Sections were deparaffinized and incubated with 5% BSA for 60 minutes. 
Cells positive for FGF-6 were detected by incubation with the primary antibody for 2 hours at room temperature 
followed by incubation with 3% hydrogen peroxide for 10 minutes. Rabbit anti-rabbit immunoglobulin G labeled 
with horseradish peroxidase was used as secondary antibody. The expression of FGF-6 or ferritin was visualized 
with 3,3-diaminobenzidinetetrahydrochloride (DAB-4HCl). The expression of FGF-6 in SSc and tumor tissues was 
quantitated by the average optical density (AOD) of the positive signal in each sample using NIH ImageJ software 
(Windows and Java-1.8.0). 
Results 
Gene-based compound heterozygosity scan identifies a novel hemochromatosis-
susceptibility gene 
To discover novel iron-overload–predisposing genes, we conducted a gene-based scan for recessive diplotypes 
composed of putative functional alleles across the exome using biobanked samples linked to electronic medical 
records obtained from a rural, genetically homogeneous population in central Wisconsin. Of the 10 000 samples 
evaluated, our transferrin saturation and diagnostic code-based phenotype algorithm identified 18 case 
individuals and 6896 controls. We estimated gametic phase on all individuals and restricted our analyses of 
diplotypes to putative functional variants. Our recessive diplotype scan identified 2 exome-wide significant 
genes (Figure 1; Table 1; supplemental Figure 3), HFE (P = 1.29 × 10−8; OR = 28.7) and FGF6 (P = 1.99 × 10−6; OR = 
22.8). For comparison, the SKAT/rvtest procedure on the FGF6 genotype data yielded an asymptotic P = 3.86 × 
10−5 and permuted P = 1.0 × 10−4. Notably, the recessive diplotype scan result exceeded exome-wide 
significance, whereas the rare variant test did not. Additionally, there was no statistical evidence of effect 
differences between females and males for the FGF6data (Mantel-Haenszel test of homogeneity P = .728). These 
results motivated our investigation of FGF-6 function and the impact of specific FGF6 variants on iron 
metabolism. 
 
Figure 1.  Manhattan plot of the gene-based recessive diplotype association results. The association P-value 
testing hemochromatosis association for each gene (−log10 p plotted on the ordinate) on different chromosomes 
is shown in alternating navy blue and yellow along the abscissa, with the experiment-wise significance level for 
the gene-based analyses across the exome (experiment-wise α = 3.14 × 10−6) depicted in red. 
 
Table 1. Significant genes identified by recessive diplotype scanning 
Chromosome  Gene  P  OR  SNPs  Case+  Case−  Control+  Contro   
chr6  HFE  1.29 × 10−8  28.6  14  8  10  189  6707  
chr12  FGF6  1.99 × 10−6  22.8  10  6  12  153  6743  
chr21  KRTAP15-1  7.55 × 10−5  6.78  5  11  7  1271  5625  
chr20  XKR7  1.18 × 10−4  43.6  7  3  15  35  6861  
chr20  CABLES2  1.28 × 10−4  42.4  7  3  15  36  6860  
chr22  THOC5  1.38 × 10−4  6.24  9  13  5  1945  4951  
The 6 most significant genes identified in the recessive diplotype scan are displayed. P values are from a 2-tailed 
Fisher exact test. 
Case+, number of iron-overload case individuals carrying recessive diplotypes with putative functional alleles; 
Case−, number of cases carrying at least 1 homolog at the gene without a putative functional allele; Control+, 
number of control individuals carrying recessive diplotypes with putative functional alleles; Control−, number of 
controls carrying at least 1 homolog at the gene without a putative functional allele; OR, Haldane odds ratio; 
SNP, number of genotyped variants per gene that were polymorphic in the samples studied. 
 
Protein-protein interaction indicates FGF-6 is involved in iron-metabolism network 
To explore the involvement of FGF6 in iron metabolism, we found evidence for FGF-6 interactions with FGFR1, 
MAPK1/3, INS, FN1, and involvement in the iron-metabolism subnetwork involving transferrin (TF), HFE, 
hepcidin antimicrobial peptide (HAMP), and SLC40A1 (supplemental Figure 4) by investigating FGF-6 protein-
protein interactions. FGF-6, also known as heparin secretory-transforming protein 2 or heparin-binding growth 
factor 6, has multiple heparin-binding sites (HBSs). Three known nonsynonymous variants located in the HBSs 
(R188Q) or flanking sites (D174V and E172X) were speculated to be important for FGF-6 function. Furthermore, 
D174V and E172X are located in the regions between FGFR-binding region (FGFR-BR-3) and HBS-1 (Figure 2). 
Hence, we studied these 3 variants in functional studies to further investigate the involvement of FGF-6 in iron 
metabolism. 
 
Figure 2.  Protein sequence alignment for FGF-4, FGF-5, and FGF-6 with heparin and FGFR-binding 
domains.Protein domains summarized from a previous FGF-6 functional study.58 Alignment and heparin and 
FGFR-binding sites/regions (HBS and FGFR-BR, respectively) are shown for FGF-4, FGF-5, and FGF-6 proteins. 
 
FGF-6 modulation of hepcidin expression and iron uptake 
To investigate the potential mechanism linking FGF-6 to iron metabolism, the effects of FGF6 on iron uptake and 
the expression of iron-metabolism genes in HepG2, HCT8, HCT116, 786-O, and HFF1 cells were evaluated. Using 
cultured cells and a ferrozine assay to detect iron, total intracellular iron concentration was significantly 
decreased in HepG2, 786-O, HCT8, HCT116, and HFF-1 cells when treating with active FGF-6 protein in a dose-
dependent manner (Figure 3; supplemental Figure 5). Testing the effect of FGF6 on the expression of a set of 
genes involved in iron metabolism (HAMP, HDAC2, HMOX1, TFRC, and HEPH), HepG2 cells were subjected to 
treatment from control or FGF-6 protein and FGF6messenger RNA (mRNA) or control and mRNA expression 
relative to GAPDH was measured in the 5 iron-metabolism genes. RT-PCR analysis revealed 
that HAMP and HDAC2 mRNA levels were significantly increased after the FGF-6 active protein introduction in 
HepG2 cells compared with treatment with PBS as control (Figure 4A). FGF6 plasmid transfection significantly 
increased HAMP, HDAC2, and HMOX1levels, whereas TFRC levels significantly decreased in HepG2 compared 
with a vector without FGF6 (Figure 4B). HEPH expression did not change with either FGF6 plasmid or FGF-6 
protein, suggesting that the effect of FGF-6 may be independent of HEPH(Figure 4A-B). 
 
Figure 3. FGF-6 active protein dosage effect on intracellular iron concentration. A ferrozine assay was applied 
for the evaluation of total cell iron content in HepG2 (human liver hepatocellular carcinoma cell line), 786-O 
(human kidney adenocarcinoma cell line), HCT-8 (human ileocecal colorectal adenocarcinoma cell line), HCT116 
(human colon carcinoma cell line), and HFF-1 (human skin fibroblast cell line) with 10 μM FAC and 500 μM 
ascorbate in cell culture media, respectively, with different concentrations of FGF-6 active protein (0 ng/mL, 2.5 
ng/mL, 25 ng/mL, and 250 ng/mL). Control group was treated with ascorbate alone. After 48-hour incubation, 
cells were lysed and iron contents were determined with the ferrozine assay. (A) Total iron content in HepG2 
cells with increasing FGF-6 protein concentration. (B) Total iron content in 786-O cells with increasing FGF-6 
protein concentration. (C) Total iron content in HCT-8 cells with increasing FGF-6 protein concentration. (D) 
Total iron content in HCT-116 cells with increasing FGF-6 protein concentration. *P< .05, **P < .01, ***P < .001. 
 
 
Figure 4.  The effect of FGF6 nonsynonymous variants on hepcidin expression and intracellular iron 
concentration. (A) The effect of FGF-6 active protein treatment on mRNA expression of several iron metabolism 
genes in HepG2 liver hepatocellular carcinoma cell culture media compared with control. Protein concentration 
was 250 ng/mL and the incubation time was 24 hours with 10 μM FAC and 500 μM ascorbate in the cell culture 
media. HAMP encodes for hepcidin. HDAC2 encodes for histone deacetylase 2. HMOX1 encodes for heme 
oxygenase 1. TFRC encodes for transferrin receptor 1 and HEPH encodes hephaestin. mRNA expression was 
quantified relative to GAPDH expression. Treatment with PBS served as control. A Student t test was used test 
for pairwise differences between sets of observations. *P < .05. Results are the mean ± standard deviation (SD) 
of 3 observations in a single experiment. (B) Iron-metabolism gene expression changes with FGF6 mRNA 
transfection in the HepG2 cell culture media after 24 hours. Vector without FGF6 served as control. A 
Student t test was used to test for pairwise differences between sets of observations. *P < .05. Results are the 
mean ± SD of 3 observations in a single experiment. (C-D) Iron-metabolism gene-expression changes after the 
transfection by FGF6 mRNA into various cell types with WT and the identified variants E172X (M1), D174V (M2), 
and R188Q (M3). Cell lines: HepG2 are liver hepatocellular carcinoma cells, HCT116 are ileocecal colorectal 
adenocarcinoma cells, and HFF-1 are human normal skin fibroblasts. A Student ttest was used to test for 
pairwise differences between sets of observations. *P < .05. Results are the mean ± SD of 3 observations in a 
single experiment. (E-F) Total intracellular iron-concentration changes after the transfection with FGF6 mRNA 
into 3 cell types with WT and the identified M1, M2, and M3 variants in the presence of FAC for 48 hours. A 
Student t test was used to test for pairwise differences between sets of observations. *P < .05; **P < .01. Results 
are the mean ± SD of 3 observations in a single experiment. (G-H) Ferritin protein level changes after the 
transfection by FGF6mRNA into the 3 cell types with WT and the identified M1, M2, and M3 variants in the 
presence of FAC for 48 hours. A Student t test was used to test for pairwise differences between sets of 
observations. *P < .05. Results are the mean ± SD of 3 observations in a single experiment. 
 
Evaluation of FGF6 variants on HAMP expression and iron concentration compared with 
WT FGF6 
To investigate the effects of the FGF6 alleles on FGF-6 function, we transfected plasmids carrying either the 
WT FGF6 or variant FGF6 with each of the 3 point mutations described in Figure 2 (supplemental Figure 6). The 
M1 (E172X) and M3 (R188Q) variants exhibited a significant downregulation of HAMP mRNA compared with WT 
in HepG2 cells (Figure 4C), HCT-116 cells (Figure 4D), 786-O (supplemental Figure 7), A498 (supplemental Figure 
7), but not HCT-8 cells (supplemental Figure 7). Evaluating the effect of M2 (D174V) on HAMP expression 
compared with WT only yielded a significant reduction in HepG2 (Figure 4C), but not in any of the other cell lines 
(Figure 4D; supplemental Figure 7). Furthermore, we noted HAMP mRNA levels in M1 and M3 transfections 
were comparable to control levels, which illustrated a strong attenuation of FGF-6 function for M1 and M3 
variants (Figure 4C-D; supplemental Figure 7). Examining the impact of specific variants on intracellular iron 
concentration in HepG2 and HCT-116 cells, M1 and M3 produced significantly elevated iron deposition (Figure 
4E-F; supplemental Figure 8) and ferritin expression (Figure 4G-H; supplemental Figure 8), indicating a deficiency 
in M1/M3 FGF6-mediated iron homeostasis. In addition, the intracellular iron-accumulation pattern was 
confirmed by immunohistochemistry (IHC) using Perls stain (supplemental Figure 9). In contrast, M2 did not 
produce a significant departure from WT in iron concentration and ferritin expression in HepG2 and HCT-116 
(Figure 4). Furthermore, TFRC expression was significantly upregulated in the presence of M3 compared with 
WT (Figure 4C). The functions mentioned were also validated in HFF-1 (supplemental Figure 8). 
Altered FGF6 gene expression in SSc and cancer 
We hypothesized that FGF-6 might be involved in human autoimmune diseases and cancers because abnormal 
iron metabolism has been reported in numerous studies.46-50 More specifically, decreased hepcidin has been 
implicated in the anemia of chronic disease, which frequently accompanies these systemic inflammatory states. 
To explore the relationship between FGF6 expression and iron deposition in autoimmune 
tissues, FGF6 expression and iron deposition in the skin lesions from SSc patients and healthy controls were 
examined. We found significantly decreased FGF-6 protein by immunohistochemistry assay (Figure 5A) and 
elevated iron deposition in SSc skin tissue by ferrozine assay (Figure 5B), especially in the epidermis. Increased 
iron deposition was confirmed by Perls stain in SSc skin tissues (supplemental Figure 10A). We also investigated 
the relationship between FGF6 protein expression with iron deposition in liver cancer tissues. We found that 
FGF-6 was significantly decreased in nonmetastatic cancer lesion tissues (Figure 5C) and the increased iron 
deposition (Figure 5D; supplemental Figure 10B). However, increased FGF-6 expression was observed in 
metastatic liver carcinoma tissue (supplemental Figure 11), suggesting that FGF-6 plays different roles in 
oncogenesis and metastasis, analogous to transforming growth factor β.51,52 
 
Figure 5.  Perls stain and ferritin expression. (A) FGF-6 protein level was evaluated by IHC assay (IHC) in skin 
tissues from SSc patients and healthy controls (Normal). Staining was visualized by Nikon microscopy; original 
magnification ×200. A Student t test was used to test for pairwise differences between AOD values between SSc 
and normal observations. The ratio of positive stain areas to the total area was used to evaluate protein levels. 
AODs were quantified by ImageJ software. **P < .01. (B) IHC with Perls Prussian Blue stain for ferritin protein 
was applied to evaluate the iron deposition in SSc skin tissues and healthy skin tissue. AOD values were 
quantified by ImageJ software. Staining was visualized by Nikon microscopy; original magnification ×200. **P < 
.01. (C) IHC of FGF-6 protein in liver cancer tissue and control tissue. AODs were quantified by ImageJ software. 
Staining was visualized by Nikon microscopy; original magnification ×200. *P < .05. (D) IHC of ferritin protein 
using Perls Prussian Blue stain in liver cancer tissue and control tissue. AODs were quantified by ImageJ 
software. Staining was visualized by Nikon microscopy; original magnification ×200. *P < .05. 
Discussion 
Iron homeostasis results from a combination of pathways and 4 main cell types: enterocyte, hepatocyte, 
macrophage, and erythroblast. The epidermal growth factor/epidermal growth factor receptor signaling 
pathway, heme production, STAT signaling, cyclic adenosine monophosphate signaling, ferritin storage, and 
bone morphogenetic protein–SMAD signaling are all involved in iron regulation. We conducted an exome-wide, 
gene-based recessive diplotype scan using putative functional variants to reveal additional genes underlying 
hemochromatosis susceptibility, an approach that can be widely applied to investigate complex disease 
susceptibility generated by compound heterozygosity and recessive single-site effects using existing exome-wide 
association genotype and sequencing data. Although the case sample size was very small, this novel scan 
identified FGF6 as being significantly associated with hemochromatosis following correction for multiple 
testing. FGF6 belongs to the paracrine FGF gene family and is largely expressed in skeletal muscle, which plays 
an important role in iron metabolism as it contains 10% to 15% of iron stores. We conducted the evolutionary 
analysis of FGF6and known iron-metabolism genes including FGFR1, TFRC, FTH1, IREB1, TF, HMOX1, ACO2, 
and HAMP (encoding hepcidin). The appearance of iron-metabolism genes can be separated into 2 
stages. TF and HMOX1, which are found in animals from Caenorhabditis elegans to Homo sapiens, indicate an 
origin in early Bilateria evolution (∼635 million years ago [Mya]). FGF6, FGFR1, ACO2, and HAMP can be found 
from Danio rerio to H sapiens, but are not present in C elegans and Drosophila, indicating emergence in early 
Vertebrata (∼485 Mya). The coappearance of these genes suggests possible coregulatory functions 
(supplemental Figure 4A). Functional experiments demonstrated that FGF-6 strongly impacted hepcidin 
expression, thereby playing a role in regulation of iron homeostasis. These results suggest FGF-6 mediates its 
effect on iron metabolism via hepcidin. The induction of hepcidin expression by FGF-6 leads to degradation of 
ferroportin through binding and internalization of ferroportin by hepcidin as shown in Figure 6. We additionally 
found that 3 FGF6 nonsynonymous variants increased intracellular iron concentrations and reduced hepcidin 
levels compared with WT FGF6, indicating loss of function. Interestingly, a genome-wide RNA interference–
profiling study reported that knockdown of FGF6 increased transferrin-mediated endocytosis.53Rs12368351, ∼8 
kb downstream of FGF6, has been associated with phosphorus levels54; and 2 SNPs, rs140668749 and 
rs10849061, within 20 kb downstream of FGF6, are associated with migraine.55,56 Previous studies have 
indicated that iron plays a role in autoimmunity and a study examining pulmonary arterial hypertension in SSc 
noted iron deposition in lung elastin fibers and giant cells,57 however, epidermal iron deposition in SSc has not 
been previously investigated. We observed that FGF-6 is involved with iron deposition in SSc and liver cancer. 
Together, these results demonstrate that FGF receptor (FGFR) signaling through FGF-6 is a critically important 
mechanism in iron metabolism. 
 
Figure 6. The proposed mechanism of FGF-6 in the regulation of hepcidin expression and iron 
concentrations. Paracrine FGF-6 interacts with FGFR with heparin or heparin sulfate proteoglycan (HPSG) as the 
cofactor to initial FGF pathway.59 Activated FGFRs have the ability to phosphorylate specific tyrosine residues 
and activate STAT3 pathway.60 Iron overload and inflammation could positively regulate hepcidin by BMP/Smad 
pathway61 and inflammatory IL-6/STAT3 pathways.62,63However, loss-of-function FGF6 variants will silence the 
FGF6-FGFR pathway, increase free heparin, and reduce expression of hepcidin, thereby decreasing the inhibition 
of ferroportin-mediated iron transfer from the intracellular compartment to the blood (ie, increasing plasma 
levels of iron). In SSc patients, IL-6 is increased so that hepcidin will be positively regulated which suppresses 
iron release to the plasma generating higher iron levels in skin cells. 
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